Rate and determinants of 10-year persistence with antihypertensive drugs

Journal of Hypertension

Volumn 23, Issue 11, 2005, Pages 2101-2107

  Van Wijk, Boris L G ^a   Klungel, Olaf H ^a,b   Heerdink, Eibert R ^a   De Boer, Anthonius ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Faculty of Sciences   (Netherlands)

Author keywords

Adherence; Antihypertensive drugs; Discontinuation; Hypertension; Persistence

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIASTHMATIC AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIGLAUCOMA AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIPARKINSON AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NEUROLEPTIC AGENT; PROPRANOLOL; SOTALOL; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; CARDIOLOGIST; CLINICAL FEATURE; COHORT ANALYSIS; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 28844436931     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000187261.40190.2e     Document Type: Article

References (30)

1. Esposti LD, Di Martine M, Saragoni S, Sgreccia A, Capone A, Buda S, Esposti ED. Pharmacoeconomics of antihypertensive drug treatment: an analysis of how long patients remain on various antihypertensive therapies. J Clin Hypertens (Greenwich) 2004; 6:76-84.
2. World Health Organization. The Atlas of Heart Disease and Stroke. World Health Organization Health Topics; 2004. Available at: http://www.who.int/ cardiovascular_diseases/resources/atlas/en/. [Accessed 27 January 2005]
3. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365:217-223.
4. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289:2534-2544.
5. Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002; 16:569-575.
6. Caro JJ, Salas M, Speckman L, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ 1999; 160:31-37.
7. Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther 2001; 23:1999-2010.
8. Degli Esposti E, Sturani A, Di Martino M, Falasca P, Novi MV, Baio G, et al. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens 2002; 16:439-444.
9. Okano GJ, Rascati KL, Wilson JP, Remund DD, Grabenstein JD, Brixner DI. Patterns of antihypertensive use among patients in the US Department of Defense database initially prescribed an angiotensin-converting enzyme inhibitor or calcium channel blocker. Clin Ther 1997; 19:1433-1445; discussion 1424-1425.
10. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998; 20:671-681.
11. McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care 1994; 32:214-226.
12. Psaty BM, Koepsell TD, Yanez ND, Smith NL, Manolio TA, Heckbert SR, et al. Temporal patterns of antihypertensive medication use among older adults, 1989 through 1992. An effect of the major clinical trials on clinical practice? JAMA 1995; 273:1436-1438.
13. Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ 1995; 311:293-295.
14. Wannemacher AJ, Schepers GP, Townsend KA. Antihypertensive medication compliance in a Veterans Affairs Healthcare System. Ann Pharmacother 2002; 36:986-991.
15. Moser M. World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension - Do These Differ From the U.S. Recommendations? Which Guidelines Should the Practicing Physician Follow? J Clin Hypertens (Greenwich) 1999; 1:48-54.
16. World Health Organization. Guidelines for ATC Classification and DDD assignment, WHO Collaborating Centre for Drug Statistics Methodology. Nordic Council on Medicines, Oslo; 1999.
17. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997; 50:105-116.
18. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care 2000; 9(9 Suppl.):2-6.
19. Cardinal H, Tatami Monfared AA, Dorais M, LeLorier J. A comparison between persistence to therapy in ALLHAT and in everyday clinical practice: a generalizability issue. Can J Cardiol 2004; 20:417-421.
20. Gregoire JP, Moisan J, Guibert R, Ciampi A, Milot A, Gaudet M, Cote I. Determinants of discontinuation of new courses of antihypertensive medications. J Clin Epidemiol 2002; 55:728-735.
21. Salvetti A, Ghiadoni L. Guidelines for antihypertensive treatment: an update after the ALLHAT study. J Am Soc Nephrol 2004; 15(Suppl. 1):S51-S54.
22. Himmelmann A, Kjeldsen SE, Hedner T. Recent hypertension guidelines: JNC-7 and 2003 ESH/ESC. Blood Press 2003; 12:196-197.
23. Bloch MJ, Basile J. Analysis of Recent Papers in Hypertension: New US Guidelines on High Blood Pressure in Children and Adolescents. J Clin Hypertens (Greenwich) 2004; 6:657-659.
24. 2003 European Society of Hypertension. European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
25. Cheung BM. Sartans for hypertension - implications of the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial. Hong Kong Med J 2004; 10:359.
26. Marentette MA, Gerth WC, Billings DK, Zarnke KB. Antihypertensive persistence and drug class. Can J Cardiol 2002; 18:649-656.
27. Degli Esposti L, Degli Esposti E, Valpiani G, Di Martino M, Saragoni S, Buda S, et al. A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin Ther 2002; 24:1347-1357; discussion 1346.
28. Haynes RB, McDonald H, Garg AX, Montagne P. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev 2002; CD000011.
29. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA 2002; 288:2880-2883.
30. Haddad M, Inch C, Glazier RH, Wilkins AL, Urbshott G, Bayoumi A, Rourke S. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database Syst Rev 2000; CD001442.